Its highly differentiated asset blends beautifully in the pharma's core therapeutic category that it has dominated with its legacy Humira, + Skyrizi and Rinvoq Other areas of I&I in development (v
(However, caution: if someone needs nitrates, they have heart disease, and PT-141 might be risky due to raising BP
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
It remains important to monitor and evaluate patients for advanced fibrosis, Sanyal says
Fiber) study recently highlighted, your gut needs to be primed. If your microbiome isnt diverse, all that fiber might just cause bloating
Expert guidance for weight loss with GLP-1 medications GLP-1 medications are changing the landscape of weight loss